WallStSmart

CVS Health Corp (CVS)vsLam Research Corp (LRCX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 1744% more annual revenue ($399.83B vs $21.68B). LRCX leads profitability with a 30.9% profit margin vs 0.4%. CVS appears more attractively valued with a PEG of 0.24. LRCX earns a higher WallStSmart Score of 74/100 (B).

CVS

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 7.3Quality: 5.0
Piotroski: 4/9Altman Z: 2.11

LRCX

Strong Buy

74

out of 100

Grade: B

Growth: 7.3Profit: 10.0Value: 4.7Quality: 7.8
Piotroski: 6/9Altman Z: 4.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVSUndervalued (+77.4%)

Margin of Safety

+77.4%

Fair Value

$340.13

Current Price

$86.86

$253.27 discount

UndervaluedFair: $340.13Overvalued
LRCXUndervalued (+13.4%)

Margin of Safety

+13.4%

Fair Value

$343.11

Current Price

$297.17

$45.94 discount

UndervaluedFair: $343.11Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVS5 strengths · Avg: 9.4/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
76.6%10/10

Earnings expanding 76.6% YoY

Market CapQuality
$105.21B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.61B8/10

Generating 2.6B in free cash flow

LRCX6 strengths · Avg: 9.7/10
Market CapQuality
$320.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
66.8%10/10

Every $100 of equity generates 67 in profit

Profit MarginProfitability
30.9%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
35.0%10/10

Strong operational efficiency at 35.0%

Altman Z-ScoreHealth
4.6510/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
23.8%8/10

Revenue surging 23.8% year-over-year

Areas to Watch

CVS4 concerns · Avg: 3.0/10
Return on EquityProfitability
2.3%3/10

ROE of 2.3% — below average capital efficiency

Profit MarginProfitability
0.4%3/10

0.4% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Debt/EquityHealth
1.243/10

Elevated debt levels

LRCX3 concerns · Avg: 2.7/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
48.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
36.6x2/10

Trading at 36.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bull Case : LRCX

The strongest argument for LRCX centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 30.9% and operating margin at 35.0%. Revenue growth of 23.8% demonstrates continued momentum.

Bear Case : CVS

The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 59.1x leaves little room for execution misses. Thin 0.4% margins leave little buffer for downturns.

Bear Case : LRCX

The primary concerns for LRCX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 48.5x leaves little room for execution misses.

Key Dynamics to Monitor

CVS profiles as a value stock while LRCX is a growth play — different risk/reward profiles.

LRCX carries more volatility with a beta of 1.79 — expect wider price swings.

LRCX is growing revenue faster at 23.8% — sustainability is the question.

CVS generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

LRCX scores higher overall (74/100 vs 65/100), backed by strong 30.9% margins and 23.8% revenue growth. CVS offers better value entry with a 77.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

Lam Research Corp

TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA

Lam Research Corporation is an American corporation that engages in the design, manufacture, marketing, and service of semiconductor processing equipment used in the fabrication of integrated circuits. Its products are used primarily in front-end wafer processing, which involves the steps that create the active components of semiconductor devices (transistors, capacitors) and their wiring (interconnects). The company also builds equipment for back-end wafer-level packaging (WLP), and for related manufacturing markets such as for microelectromechanical systems (MEMS). The company is headquartered in Fremont, California, in the Silicon Valley.

Want to dig deeper into these stocks?